ClinicalTrials.gg
CompletedNCT01193699PEGINVERAUpdated Jan 30, 2018

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera

A Phase 1/2 interventional study of PEG-P-INF alpha-2b (P1101) in Polycythemia Vera, sponsored by AOP Orphan Pharmaceuticals AG. Completed at 6 sites in Austria. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-01-30.

Sponsored by AOP Orphan Pharmaceuticals AG · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera — 1 open to participants now, 3 under way, 2 of them phase 3. ropeginterferon alfa-2b · Polycythemia Vera.

Planned enrollment
9th of 11
24 · median 49
Started
2010
the only one that year
Phase 1/2
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
4 of 11
AOP Orphan Pharmaceuticals AG

Among the 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera, this one is the 9th largest by planned enrollment, is the only one that started in 2010, is the only one in phase 1/2, and was the 1st registered.

Polycythemia Vera

279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

1 of the 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ropeginterferon alfa-2b

ropeginterferon alfa-2b: first FDA approval 2021 (BESREMI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera, or all of them as a file.
02

Study summary

The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomarker modulation will be performed.

03

Conditions studied

  • Polycythemia Vera

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained prior to any study specific screening activities and able to comply with this protocol.
  2. Patients age ≥18 years
  3. Confirmed diagnosis of PV according to either the WHO criteria (2008, appendix 6) or the PSVG (appendix 7) criteria plus JAK-2 positivity, including newly diagnosed, pre-treated and on cytoreductive therapy.
  4. performance status ≤ 2
  5. If female of - have a negative urine pregnancy test result within 7 days prior to the scheduled first application of product and agree to employ adequate measures for the duration of the study.

Exclusion criteria

Exclusion criteria:

  1. Diagnosis of any other myeloproliferative disorder
  2. Any illness or surgery within 4 weeks prior to dosing
  3. Systemic infections, e.g. , , or at screening
  4. Uncontrolled hypertension (systolic > 150 mmHg and diastolic > 100 mmHg, or clinically significant (i.e. active) cardiovascular disease: CVA/stroke (≤ 3 months prior to enrolment), myocardial infarction (≤ 3 months prior to enrolment), significant coronary artery stenosis, unstable angina, (NYHA) Class 2 or greater Congestive heart failure, or serious cardiac arrhythmia requiring medication.
  5. Previous treatment with Interferon for PV
  6. Concurrent treatment with cytoreductive agents other than Hydroxyurea and agents of any type
  7. History of malignant disease, including solid tumours and haematological (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years
  8. History of severe allergic (like anaphylaxis) or reactions (like angioedema), any known or suspected intolerance to the investigational product.
  9. Use of any investigational drug or participation in any investigational drug study within the last 4 weeks
  10. Clinically significant history or known presence of psychiatric disorders, including but not limited to depression, anxiety and sleep disorders
  11. Organ transplant, past or planned
  12. Inadequate liver function defined by serum (total) > 2,5 x and/ or and ALT > 2,5 x ULN
  13. Clinically significant findings
  14. History of renal disease requiring haemodialysis or seizure disorder requiring anticonvulsant therapy
  15. Pregnant or lactating females (pregnancy test to be assessed within 7 days prior to study treatment start)
  16. Acute or chronic infections or diseases (collagen diseases, polyarthritis, immune thrombocythemia, thyroiditis, psoriasis, lupus nephritis or any other autoimmune disorder).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    P1101

    Drug: PEG-P-INF alpha-2b (P1101)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    The definition of MTD is based on a 3+3 dose escalation design. MTD is defined as the next lower dose of that dose which was considered to be untolerated (observed DLT frequency at least 2 out of 3 in one cohort or at least 2 out of six patients in 2 cohorts).

    Time frame: The incidence of dose limiting toxicities (DLTs), which define the MTD are assessed continously until achievement of MTD.

07

Study locations

6 sites
  • Innsbruck, Tirol 6020, Austria
  • Wels, Upper Austria 4600, Austria
  • Salzburg, 5020, Austria
  • Vienna, 1090, Austria
  • Vienna, 1140, Austria
  • Vienna, 1220, Austria
08

References and documents

Publications

  • Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10. PubMed 26261238 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2010 to primary completion in Jan 2018, 89 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2010
First posted
Sep 2, 2010
StartActual
Aug 2010
Primary completionActual
Jan 25, 2018
CompletionActual
Jan 25, 2018
Last update
Jan 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01193699
Lead sponsor
AOP Orphan Pharmaceuticals AG
Responsible party
Sponsor
First posted
Sep 2, 2010
Start date
Aug 2010
Primary completion
Jan 25, 2018
Completion
Jan 25, 2018
Last update
Jan 30, 2018

Study contacts

Barbara Grohmann-Izay, MD
study director · AOP Orphan Pharmaceuticals AG

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropeginterferon alfa-2b

Start the discussion